Top Markets
#1 Akedo Akedo +57.65%
#2 Glidr Glidr +51.75%
#3 DOVU DOVU +48.04%
#4 Velvet Velvet +42.35%
#5 Black Phoenix Black Phoenix +34.54%
#6 τemplar τemplar +23.53%
#7 Cross Cross +20.01%
#8 Ribbita by Virtuals Ribbita by Virtuals +16.20%
#9 Not in Employment, Education, or Training Not in Employment, Education, or Training +15.39%
#10 Perle Perle +15.05%
Coin of the day
Akedo Akedo
Configuración
Idioma
ESPAñOL
Moneda
USD
Tema
Evofem Biosciences, Inc. Evofem Biosciences, Inc.

Evofem Biosciences, Inc.

EVFM
Clasificación en acciones #38408
Evofem Biosciences, Inc. operates as a biopharmaceutical enterprise dedicated... Evofem Biosciences, Inc. operates as a biopharmaceutical enterprise dedicated to innovating and bringing to market treatments that address critical underserved areas in women's sexual and reproductive health. Their leading commercial offering is Phexxi, a vaginal gel specifically designed as a contraceptive. Additionally, the company is actively advancing EVO100, an antimicrobial vaginal gel under development, intended to prevent the urogenital spread of both Chlamydia trachomatis and Neisseria gonorrhoeae infections in women. The company's main office is situated in San Diego, California.
Precio por acción
$0.007524
Capitalización bursátil
$997.16K
Cambio (1 día)
-5.95%
Cambio (1 año)
-22.43%
País
US
Comercio Evofem Biosciences, Inc. (EVFM)

Categoría

Healthcare
Ganancias de Evofem Biosciences, Inc. (EVFM)
Ganancias en 2026 TTM: 0
Secondo gli ultimi rapporti finanziari di Evofem Biosciences, Inc., gli utili attuali della società sono 0. Nel 2026, la società ha registrato un utile di 0, igual a agli utili del 2026, che erano di 0. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Historial de ganancias de Evofem Biosciences, Inc. desde 2026 hasta 2026
Ganancias al final de cada año
Año Ganancias Cambiar
Not enough data for the provided dates.
Ganancias de empresas similares o competidoras
Empresa Ganancias Diferencia de ganancias País
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
$3.01B -
BE